Marco Siringo

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2026

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Journal: Tumori

Published: May 04, 2026

Organotropism-specific circulating tumor cells profiles: Morphology and heterotypic clustering predict metastatic sites in liquid biopsy of solid tumors.

Organotropism-specific circulating tumor cells profiles: Morphology and heterotypic clustering predict metastatic sites in liquid biopsy of solid tumors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 29, 2026

The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age.

The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age.

Journal: Journal of translational medicine

Published: September 22, 2025

The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.

The role of germline mutations in non-small cell lung cancer: A systematic review of emerging genetic drivers and clinical implications.

Journal: Critical reviews in oncology/hematology

Published: August 19, 2025

Prognostic Value of Circulating Tumor Cells and Cancer Associated Macrophage-Like Cells in Metastatic Non-Small Cell Lung Cancer Patients: A Retrospective Exploratory Analysis.

Prognostic Value of Circulating Tumor Cells and Cancer Associated Macrophage-Like Cells in Metastatic Non-Small Cell Lung Cancer Patients: A Retrospective Exploratory Analysis.

Journal: Oncology research

Published: July 01, 2025

Relationship between single-nucleotide polymorphisms and cancer immunotherapy efficacy and toxicity: a systematic review.

Relationship between single-nucleotide polymorphisms and cancer immunotherapy efficacy and toxicity: a systematic review.

Journal: Frontiers in oncology

Published: June 25, 2025

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis.

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis.

Journal: Molecular oncology

Published: April 08, 2025

Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer.

Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer.

Journal: Cancers

Published: January 28, 2025

Immunological Network Signature of Naïve Non-Oncogene-Addicted Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Therapy: A Pilot Study.

Immunological Network Signature of Naïve Non-Oncogene-Addicted Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Therapy: A Pilot Study.

Journal: Cancers

Published: January 22, 2025

Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.

Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.

Journal: Biomedicines

Published: September 11, 2024

Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients.

Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients.

Journal: Frontiers in immunology

Published: August 21, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026